Dualitas Therapeutics emerged from stealth mode following a $65 million Series A financing co-led by Versant Ventures and Qiming Venture Partners USA. The Bay Area biotech aims to develop bispecific antibodies targeting immune and inflammatory diseases. The company’s scientific approach focuses on novel modalities that engage multiple targets simultaneously to enhance therapeutic specificity and efficacy. Strategic investors include established pharma and venture firms, underpinning strong confidence in Dualitas’s platform technology and pipeline potential for challenging indications.